Tularemia: Retrospective review of 10 years' experience in Arkansas

Clinical Pediatrics

Volumn 50, Issue 1, 2011, Pages 64-68

  Snowden, Jessica ^a   Stovall, Stephanie ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

general pediatrics; infectious diseases

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; GENTAMICIN;

CLINICAL FEATURE; CONVALESCENCE; DRUG TREATMENT FAILURE; HUMAN; MORBIDITY; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; SEROLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TULAREMIA; UNITED STATES;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ARKANSAS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FEVER; GENTAMICINS; HUMANS; INFANT; LYMPHATIC DISEASES; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TULAREMIA;

EID: 78650224986     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922810381425     Document Type: Review

References (18)

1. Staples JE, Kubota KA, Chalcraft LG, Mead PS, Petersen JM Epidemiologic and molecular analysis of human tularemia, United States, 1964-2004. Emerg Infect Dis. 2006 ; 12: 1113-1118.
2. Centers for Disease Control and Prevention. Tularemia- Missouri, 2000-2007. MMWR Morb Mortal Wkly Rep. 2009 ; 58: 744-748.
3. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001 ; 285: 2763-2773.
4. Tarnvik A., Chu MC New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci. 2007 ; 1105: 378-404.
5. McLendon MK, Apicella MA, Allen LA Francisella tularensis: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol. 2006 ; 60: 167-185.
6. Centers for Disease Control and Prevention. Tularemia- United States, 1990-2000. MMWR Morb Mortal Wkly Rep. 2002 ; 51: 181-184.
7. Raghavan M., Glickman N., Moore G., Caldanaro R., Lewis H., Glickman L. Prevalence of and risk factors for canine tick infestation in the United States, 2002-2004. Vector Borne Zoonotic Dis. 2007 ; 7: 65-75.
8. Cross JT Jr, Schutze GE, Jacobs RF Treatment of tularemia with gentamicin in pediatric patients. Pediatr Infect Dis J. 1995 ; 14: 151-152.
9. Ellis J., Oyston PC, Green M., Titball RW Tularemia. Clin Microbiol Rev. 2002 ; 15: 631-646.
10. Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci. 2007 ; 1105: 1-29.
11. Assal N., Blenden DC, Price ER Epidemiologic study of human tularemia reported in Missouri, 1949-65. Public Health Rep. 1967 ; 82: 627-632.
12. Centers for Disease Control and Prevention. Outbreak of tick-borne tularemia-South Dakota. MMWR Morb Mortal Wkly Rep. 1984 ; 33: 601-602.
13. Taylor JP, Istre GR, McChesney TC, Satalowich FT, Parker RL, McFarland LM Epidemiologic characteristics of human tularemia in the southwest-central states, 1981-1987. Am J Epidemiol. 1991 ; 133: 1032-1038.
14. Hofinger DM, Cardona L., Mertz GJ, Davis LE Tularemic meningitis in the United States. Arch Neurol. 2009 ; 66: 523-527.
15. Meric M., Willke A., Finke EJ, et al. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS. 2008 ; 116: 66-73.
16. Penn RL, Kinasewitz GT Factors associated with a poor outcome in tularemia. Arch Intern Med. 1987 ; 147: 265-268.
17. Brouillard JE, Terriff CM, Tofan A., Garrison MW Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents. Pharmacotherapy. 2006 ; 26: 3-14.
18. Urich SK, Petersen JM In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother. 2008 ; 52: 2276-2278.